Condensed Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue:
Licensing fees	$ 240,550	$ 176,922	$ 729,095	$ 513,322
Peptide and consumer product sales	176,669	100,884	605,190	576,165
Consumer product sales to affiliated company	51,852	116,901	285,730	355,951
Total revenue	469,071	394,707	1,620,015	1,445,438
Cost of revenue:
Cost of peptide and consumer product sales	113,407	70,834	380,543	409,829
Cost of consumer product sales to affiliated company	21,832	56,961	128,684	191,486
Total cost of revenue	135,239	127,795	509,227	601,315
Gross profit	333,832	266,912	1,110,788	844,123
Operating expenses:
Research and development	133,009	109,221	308,036	425,131
Marketing and business development	302,040	225,732	874,791	674,187
General and administrative	418,868	327,162	1,132,679	1,043,843
Accounting, legal and professional fees	205,192	168,043	605,615	477,676
Depreciation and amortization	22,896	27,845	68,054	82,609
Total operating expenses	1,082,005	858,003	2,989,175	2,703,446
Loss from operations	(748,173)	(591,091)	(1,878,387)	(1,859,323)
Other income (expense):
Interest income	133	704	1,257	2,836
Amortization of debt issuance costs	(50,673)	0	(112,913)	0
Equity in income (loss) of affiliated company	14,674	(23,373)	(32,916)	(74,446)
Change in fair value of option to purchase interest in affiliated company	(1,145)	8,143	(12,362)	(9,293)
Total other income (expense), net	(37,011)	(14,526)	(156,934)	(80,903)
Net loss and comprehensive loss	$ (785,184)	$ (605,617)	$ (2,035,321)	$ (1,940,226)
Basic and diluted net loss per share (in Dollars per share)	$ (0.02)	$ (0.01)	$ (0.04)	$ (0.04)
Weighted average shares outstanding (in Shares)	49,720,255	49,720,255	49,720,255	49,720,255